AMED 10th Anniversary Symposium – retrospective and prospective

Message

The Japan Agency for Medical Research and Development（AMED） was established in 2015 as a funding agency that has a central role in promoting research and development in the medical field and improving the research environment in Japan, under the national “Healthcare and Medical Strategy.” AMED has worked on building and enhancing the management function of research and development management to maximize our work.

To commemorate this 10th anniversary, we are pleased to hold the symposium, reviewing our work through keynote lectures and discussions with experts, and sharing the future direction of research and development to the public and stakeholders. We look forward to your participation.

Overview

■Date

March 10, 2025　9:30～18:00
（Reception open 8:45 AM JST）

■Venue

Hitotsubashi Hall
Hitotsubashi Hall,National Center of Sciences Building 2F,2-1-2 Hitotsubashi,Chiyoda-ku,Tokyo 101-8439

■Participation style

In person or online

■Participation fee:

Free

Program（TBD）

Time	Program	Presenters
9:30 - 9:35	Opening Remarks	Dr. MISHIMA Yoshinao, President of AMED
9:35 - 9:40	Remarks from our honored guests 1	Cabinet Office Ministry of Education, Culture, Sports, Science and Technology Ministry of Health, Labor and Welfare Ministry of Economy, Trade and Industry
9:40 - 9:45	Remarks from our honored guests 2
9:45 - 9:50	Remarks from our honored guests 3
9:50 - 9:55	Remarks from our honored guests 4
9:55 - 10:15	Speech by Dr.MISHIMA, President of AMED （Reviewing FY2020–FY2024）	Dr. MISHIMA Yoshinao, President of AMED
10:15 - 14:30	Keynote Speech 1～5 （11:55～13:20　Lunch Break）	Prof. MIYAZONO Kohei The University of Tokyo / RIKEN(National Research and Development Agency) Dr. Tara A. Schwetz The U.S. National Institutes of Health UK Government Ms. Signe Ratso European Commission Sir Jeremy Farrar World Health Organization
14:30 - 15:00	Coffee Break
15:00 - 16:20	Panel Discussion 1 COVID-19: What we've experienced and What We should Prepare.	[Moderator] Dr. HAMAGUCHI Michinari, Director General of SCARDA [Panelist] Dr. Jeanne Marrazzo, Director, NIAID, USA Dr. Nancy J. Sullivan, Director, NEIDL at Boston University Dr. Richard J. Hatchett, CEO, CEPI
16:20 - 17:40	Panel Discussion 2 Getting inside scoop on Drug Discovery Ecosystem	[Moderator] Ms. OISHI Keiko President and COO of CMIC HOLDINGS Co., Ltd. [Panelist] Ms. AKIEDA Shizuka CEO, Cyfuse Biomedical K.K. Ms. SHIOHARA Azusa Principal, The University of Tokyo Edge Capital Partners Co., Ltd. Dr. SUZUKI Rami CEO, ARC Therapies Inc. Dr. YOSHIKAWA Mayu Senior Advisor, ARCH Venture Partners
17:40 - 17:45	Closing Remarks

※Programs are subject to change.

Registration

Presenters

■Keynote Speech

Distinguished University Professor, Graduate School of Medicine, The University of Tokyo MIYAZONO Kohei
―Profile―
1981	M.D. (Faculty of Medicine, The University of Tokyo)
1986	Assistant Member and Associate Member, Ludwig Institute for Cancer Research, Uppsala, Sweden (until 1995).
1988	Assistant Professor, Third Department of Internal Medicine, The University of Tokyo.
1995	Member and Chief, Department of Biochemistry, The Cancer Institute, Japanese Foundation for Cancer Research.
2000	Professor and Chair, Department of Molecular Pathology, Graduate School of Medicine, The University of Tokyo.
2011	Dean, Graduate School of Medicine, The University of Tokyo (until 2019).
2017	Member of the Japan Academy.
2019	Executive Vice President, The University of Tokyo.
2021	Distinguished University Professor, The University of Tokyo.
2022	Executive Director, RIKEN/Special University Professor Emeritus, The University of Tokyo.
2022	Team Leader, RIKEN Center for Integrative Medical Sciences, Laboratory for Cancer Invasion and Metastasis.

■Panel Discussion 2
　Getting inside scoop on Drug Discovery Ecosystem

[Moderator]

Representative Director, President and COO, CMIC HOLDINGS Co., Ltd. OISHI Keiko
―Profile―
1982	M.D. Biological Sciences (Graduate School of Science, The University of Tokyo).
1982	Nikkei McGraw-Hill, Inc.
1989	Genentech Japan, Inc.
1996	Manager of the Strategy Development Department, CMIC Co., Ltd.
2000	Director, CMIC Co., Ltd.
2013	Executive Vice President, CMIC Co., Ltd.
2018	Representative Director, President and COO, CMIC HOLDINGS Co., Ltd.

[Panelist]

Board Director CEO, Cyfuse Biomedical K.K. AKIEDA Shizuka
―Profile―
2004	Regenerative medicine and Gene therapy Projects at Kyushu University Hospital.
2010	Cyfuse as a startup member, involved in NEDO projects and others as principal researchers and involved in biomedical venture business as Head of R＆D Division leading number of projects internally and collaboratively.
2017	Received the Japan Science and Technology Agency President's Award at the University-Originated Startup Award Received the Science Council of Japan President's Award at Industry-Academia-Government Collaboration Honorary Award.
2019	Received the Small and Medium Enterprise Agency Secretary Award in JAPAN VENTURE AWARDS.
2022	The company was listed on the Tokyo Stock Exchange Growth Market. As a newly listed startup, it is committed to creating markets and industries in advanced medical fields through the development of Japan-originated and world-first products, contributing to society globally with Japan Quality manufacturing. Served as the director of the Japan Bioindustry Association and a member of the International Committee of the Japanese Society for Regenerative Medicine.

Representative Director and CEO, ARC Therapies Inc. SUZUKI Rami
―Profile―
1999	Ph.D. in medicine from University College London Subsequent postdoctoral research at Imperial College.
2001	Venture capitalist of European Life Sciences, ITX Corporation Corporate Venture Capital.
2004	Corporate officer in charge of business development, Eisai Co., Ltd.
2017	Head of Business Development and division head of Medical Affair, Janssen Pharma K.K.
2020	CEO and Representative Director, Ferring Pharma KK.
2021	President and Representative Director, Moderna Japan.
2024	Representative Director and CEO, ARC Therapies Inc.

Principal, The University of Tokyo Edge Capital Partners Co., Ltd. SHIOHARA Azusa
―Profile―
2013	Bachelor of Pharmacy, The University of Tokyo.
2015	MSc in Pharmaceutical Sciences, The University of Tokyo.
2015	Joined Arthur D. Little Japan.
2019	Manager, Arthur D. Little Japan.
2021	MBA, London Business School.
2021	Joined The University of Tokyo Edge Capital Partners Co., Ltd.
2023	Principal, The University of Tokyo Edge Capital Partners Co., Ltd.

Senior Advisor, ARCH Venture Partners YOSHIKAWA Mayu
―Profile―
2014	Earned a Ph.D. in Life Sciences from the Graduate School of Frontier Sciences, University of Tokyo. Joined McKinsey ＆ Company.
2016	Joined a Japanese venture capital firm, leading bio investments and acceleration programs.
2023	Became a Senior Advisor at ARCH Venture Partners, focusing on company creation and business development leveraging Japanese academic technologies. Concurrently involved in the management of two biotech startups in Japan and the US.

Access

Hitotsubashi Hall at Hitotsubashi University
Hitotsubashi Hall,National Center of Sciences Building 2F,
2-1-2 Hitotsubashi,Chiyoda-ku,Tokyo
101-8439

-By train（Subway）-
Tokyo Metoro Hanzomon Line/Toei Mita Line/Toei Shinjuku Line “Jinbocho” Exit A9
Tokyo Metoro Tozai Line “Takebashi” Exit 1b
3-5minutes walk from the stations
https://www.hit-u.ac.jp/hall/accessjp.html

Contact

Secretariat of AMED 10th Anniversary Symposium

Shinjuku i-LAND Tower 6 Chome-5-1 Nishishinjuku, Shinjuku City, Tokyo 163-1390
Business Hour: 10:00 - 17:00（Weekdays except Japanese holiday）
Tel：+81-(0)50-1748-7112
E-mail：amed-unei@his-world.com